{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:18:50Z","timestamp":1792513130242,"version":"4.5.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To introduce a vitrectomy technique for the submacular hemorrhage (SMH) combined with subretinal tenecteplase injection, intravitreal conbercept administration, perfluoropropane gas tamponade, and to evaluate its efficacy and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In this single-center, prospective, interventional study, patients underwent 25-gauge vitrectomy with subretinal tenecteplase and intravitreal conbercept injection, followed by 0.5 to 1.0 mL of pure perfluoropropane gas tamponade. The best-corrected visual acuity and central retinal thickness were assessed at baseline, and 1 month, 3 months, and 6 months postoperatively. Favorable outcome was defined as a best-corrected visual acuity \u22640.5 logarithm of the minimum angle of resolution at 6 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Twenty eyes of 20 patients with treatment-na\u00efve spontaneous SMH (\u226430 days) secondary to polypoidal choroidal vasculopathy (70%) or retinal arterial macroaneurysms (30%) were included. Mean central retinal thickness significantly decreased from 887.1 \u00b1 52.2\n                      <jats:italic toggle=\"yes\">\u00b5<\/jats:italic>\n                      m to 276.7 \u00b1 83.8\n                      <jats:italic toggle=\"yes\">\u00b5<\/jats:italic>\n                      m (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) at 6 months. Notably, 75% of the treated eyes (13 out of 20) achieved a favorable outcome (best-corrected visual acuity \u22640.5 logarithm of the minimum angle of resolution; Snellen equivalent \u2248 20\/63). Pearson correlation analysis revealed that the SMH onset-vitrectomy interval was significantly negatively correlated with a favorable outcome (r = \u22120.452,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.045). After adjusting for potential interaction effect, the SMH onset-vitrectomy interval remained a statistically significant predictor of worse logarithm of the minimum angle of resolution best-corrected visual acuity (odds ratio = 1.023, 95% confidence interval, 1.013\u20131.034,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The present technique for treatment-na\u00efve spontaneous SMH, in combination with subretinal tenecteplase injection, intravitreal conbercept administration, and perfluoropropane gas tamponade, demonstrated potential for visual improvement in eyes treated within 30 days of SMH onset.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000004725","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T21:00:15Z","timestamp":1762894815000},"page":"713-721","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["VITRECTOMY WITH SUBRETINAL TENECTEPLASE AND INTRAVITREAL CONBERCEPT FOR SUBMACULAR HEMORRHAGE"],"prefix":"10.1097","volume":"46","author":[{"given":"Mingwei","family":"Cui","sequence":"first","affiliation":[{"name":"Lunan Eye Hospital, Linyi, China; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Zhen","sequence":"additional","affiliation":[{"name":"Lunan Eye Hospital, Linyi, China; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9159-7972","authenticated-orcid":false,"given":"Shancheng","family":"Si","sequence":"additional","affiliation":[{"name":"Beijing Tsinghua Changgung Hospital Eye Center, Beijing Visual Science and Translational Eye Research Institute (BERI), Tsinghua Medicine, Tsinghua University, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260324","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1097\/IAE.0000000000003879","article-title":"Displacement of submacular hemorrhage with vitrectomy combined with subretinal balanced salt solution and air","volume":"43","author":"Handa","year":"2023","journal-title":"Retina"},{"key":"R2-20260324","doi-asserted-by":"crossref","first-page":"e706","DOI":"10.1111\/aos.14676","article-title":"Massive submacular haemorrhage in polypoidal choroidal vasculopathy versus typical neovascular age-related macular degeneration","volume":"99","author":"Cho","year":"2021","journal-title":"Acta Ophthalmol"},{"key":"R3-20260324","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/IAE.0000000000002384","article-title":"Posttreatment polyp regression and risk of massive submacular hemorrhage in eyes with polypoidal choroidal vasculopathy","volume":"40","author":"Cho","year":"2020","journal-title":"Retina"},{"key":"R4-20260324","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ajo.2016.06.014","article-title":"Incidence rate of massive submacular hemorrhage and its risk factors in polypoidal choroidal vasculopathy","volume":"169","author":"Cho","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"R5-20260324","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1186\/s12886-024-03687-0","article-title":"Two-year outcomes of intravitreal conbercept therapy for polypoidal choroidal vasculopathy","volume":"24","author":"Liu","year":"2024","journal-title":"BMC Ophthalmol"},{"key":"R6-20260324","doi-asserted-by":"crossref","first-page":"e12795","DOI":"10.1002\/rth2.12795","article-title":"Alteplase or tenecteplase for thrombolysis in ischemic stroke: an illustrated review","volume":"6","author":"Zhu","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"R7-20260324","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s00417-017-3648-3","article-title":"Massive subretinal and subretinal pigment epithelial hemorrhage displacement with perfluorocarbon liquid using a two-step vitrectomy technique","volume":"255","author":"Fleissig","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R8-20260324","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1016\/j.clinthera.2024.08.014","article-title":"Optimizing acute ischemic stroke outcomes: the role of tenecteplase before mechanical thrombectomy","volume":"46","author":"Haj Mohamad Ebrahim Ketabforoush","year":"2024","journal-title":"Clin Ther"},{"key":"R9-20260324","doi-asserted-by":"crossref","first-page":"107592","DOI":"10.1016\/j.jstrokecerebrovasdis.2024.107592","article-title":"Multicenter exploration of tenecteplase transition factors: a quantitative analysis","volume":"33","author":"Prasad","year":"2024","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"R10-20260324","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1136\/bjo.2009.158170","article-title":"Management of submacular haemorrhage in age-related macular degeneration with intravitreal tenecteplase","volume":"94","author":"McAllister","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"R11-20260324","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3341\/kjo.2016.30.3.192","article-title":"Management of acute submacular hemorrhage with intravitreal injection of tenecteplase, anti-vascular endothelial growth factor and gas","volume":"30","author":"Lee","year":"2016","journal-title":"Korean J Ophthalmol"},{"key":"R12-20260324","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/IAE.0000000000002035","article-title":"Short-term efficacy of conbercept and ranibizumab for polypoidal choroidal vasculopathy","volume":"39","author":"Huang","year":"2019","journal-title":"Retina"},{"key":"R13-20260324","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1007\/s00417-025-06780-2","article-title":"Clinical characteristics of optic neuritis following COVID-19 during Omicron outbreak in China","volume":"263","author":"Sun","year":"2025","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R14-20260324","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s10384-022-00910-7","article-title":"Postoperative follow-up of submacular hemorrhage displacement treated with vitrectomy and subretinal injection of tissue plasminogen activator: ultrawide-field fundus autofluorescence imaging in gas-filled eyes","volume":"66","author":"Fukuda","year":"2022","journal-title":"Jpn J Ophthalmol"},{"key":"R15-20260324","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1097\/IAE.0000000000001030","article-title":"Tissue plasminogen activator for subfoveal hemorrhage due to age-related macular degeneration: comparison of 3 treatment modalities","volume":"36","author":"Fassbender","year":"2016","journal-title":"Retina"},{"key":"R16-20260324","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s10384-019-00679-2","article-title":"Outcomes of vitrectomy combined with subretinal tissue plasminogen activator injection for submacular hemorrhage associated with polypoidal choroidal vasculopathy","volume":"63","author":"Kimura","year":"2019","journal-title":"Jpn J Ophthalmol"},{"key":"R17-20260324","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1001\/jamaophthalmol.2024.4297","article-title":"Tissue plasminogen activator or perfluoropropane for submacular hemorrhage in age-related macular degeneration: a factorial randomized clinical trial","volume":"142","author":"Murphy","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"R18-20260324","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1038\/s41433-022-02222-z","article-title":"Na\u00efve subretinal haemorrhage due to neovascular age-related macular degeneration. pneumatic displacement, subretinal air, and tissue plasminogen activator: subretinal vs intravitreal aflibercept-the native study","volume":"37","author":"Iglicki","year":"2023","journal-title":"Eye (Lond)."},{"key":"R19-20260324","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/IAE.0000000000001931","article-title":"Vitrectomy with subretinal tissue plasminogen activator and gas tamponade for subfoveal hemorrhage: prognostic factors and clinical outcomes","volume":"39","author":"Plemel","year":"2019","journal-title":"Retina"},{"key":"R20-20260324","doi-asserted-by":"crossref","first-page":"38","DOI":"10.4274\/tjo.galenos.2020.72540","article-title":"Subretinal coapplication of tissue plasminogen activator and bevacizumab with concurrent pneumatic displacement for submacular hemorrhages secondary to neovascular age-related macular degeneration","volume":"51","author":"Avc\u0131","year":"2021","journal-title":"Turk J Ophthalmol"},{"key":"R21-20260324","doi-asserted-by":"crossref","first-page":"e e582","DOI":"10.1016\/j.jcjo.2023.10.005","article-title":"Early surgical displacement of submacular hemorrhage without tissue plasminogen activator use: one-year outcomes","volume":"59","author":"Abdulaal","year":"2024","journal-title":"Can J Ophthalmol"},{"key":"R22-20260324","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ophtha.2014.07.027","article-title":"Displacement of submacular hemorrhages in age-related macular degeneration with subretinal tissue plasminogen activator and air","volume":"122","author":"Kadonosono","year":"2015","journal-title":"Ophthalmology"},{"key":"R23-20260324","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/ICB.0b013e31824daeb3","article-title":"Subretinal tenecteplase injection in a submacular hemorrhage from polypoidal choroidal vasculopathy: a case report","volume":"6","author":"Kwon","year":"2012","journal-title":"Retin Cases Brief Rep"},{"key":"R24-20260324","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/j.1442-9071.2006.01369.x","article-title":"Investigation of the safety of tenecteplase to the outer retina","volume":"34","author":"McAllister","year":"2006","journal-title":"Clin Exp Ophthalmol"},{"key":"R25-20260324","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.ophtha.2023.04.014","article-title":"Surgery, tissue plasminogen activator, antiangiogenic agents, and age-related macular degeneration study: a randomized controlled trial for submacular hemorrhage secondary to age-related macular degeneration","volume":"130","author":"Gabrielle","year":"2023","journal-title":"Ophthalmology"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004725","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T16:07:35Z","timestamp":1774368455000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004725"}},"subtitle":["A Prospective Interventional Study"],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004725","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"value":"0275-004X","type":"print"},{"value":"1539-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]}}}